ENMD-2076

Cat. No.: OB0225WX-2398

Appearance: Solid

Purity: ≥99%

Identity: Confirmed by NMR, and HPLC.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: ENMD-2076 is a selective kinase inhibitor targeting Aurora A (IC50: 14 nM) and Flt3 (IC50: 1.86 nM), showing 25-fold higher selectivity for Aurora A over Aurora B.

Synonym: 934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; Enmd-2076 free base; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; R-440; 4-Pyrimidinamine, 6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-((1E)-2-phenylethenyl)-; (E)-N-(5-methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine.; 4-Pyrimidinamine, 6-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(1Z)-2-phenylethenyl]-; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-((E)-2-phenylethenyl)pyrimidin-4-amine; N-(5-methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; 6-(4-Methyl-1-piperazinyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]-4-pyrimidinamine

CAS No.: 934353-76-1

Compound CID: 16041424

Formula: C₂₁H₂₅N₇

Formula Weight: 375.47

Specification

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: ENMD-2076 is applied in oncology research as a multi-target kinase inhibitor with high affinity for Aurora A and VEGFR2 to investigate the regulation of mitosis and the suppression of tumor vascular signaling.